Second primary malignancies
| SPM . | Rd continuous (n = 532) . | Rd18 (n = 540) . | MPT (n = 541) . |
|---|---|---|---|
| Invasive, n (%) | 36 (7) | 38 (7) | 46 (9) |
| Hematologic | 4 (1) | 2 (<1) | 14 (3) |
| AML | 1 (<1) | 1 (<1) | 5 (1) |
| MDS | 2 (<1) | 1 (<1) | 5 (1) |
| MDS to AML | 0 | 0 | 4 (1) |
| B-cell leukemia | 1 (<1) | 0 | 0 |
| Solid tumor | 32 (6) | 37 (7) | 32 (6) |
| SPM . | Rd continuous (n = 532) . | Rd18 (n = 540) . | MPT (n = 541) . |
|---|---|---|---|
| Invasive, n (%) | 36 (7) | 38 (7) | 46 (9) |
| Hematologic | 4 (1) | 2 (<1) | 14 (3) |
| AML | 1 (<1) | 1 (<1) | 5 (1) |
| MDS | 2 (<1) | 1 (<1) | 5 (1) |
| MDS to AML | 0 | 0 | 4 (1) |
| B-cell leukemia | 1 (<1) | 0 | 0 |
| Solid tumor | 32 (6) | 37 (7) | 32 (6) |
AML, acute myeloid leukemia; MDS, myelodysplastic syndromes.